drugset / Trial / NCT01311635

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

NCT01311635

Phase 1 Completed 16 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to study the relative bioavailability of AZD1981 when using a new tablet compared to the current tablet.

Timeline

Start
2011-04
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1981 Small molecule 300 mg Oral

Indications

No indication recorded.